RT Journal
A1 George TJ, Arnaoutakis GJ, Shah AS
T1 LUng transplant in idiopathic pulmonary fibrosis
JF Archives of Surgery
JO Archives of Surgery
YR 2011
FD October 1
VO 146
IS 10
SP 1204
OP 1209
DO 10.1001/archsurg.2011.239
UL http://dx.doi.org/10.1001/archsurg.2011.239
AB Objective 
                  To review the present status of lung transplant (LTx) in patients with idiopathic pulmonary fibrosis (IPF).Data Sources 
                  Current English-language literature review using MEDLINE.Study Selection 
                  Prospective and retrospective trials, series, reviews, databases, and editorials regarding the clinical and basic science aspects of LTx in patients with IPF.Data Extraction 
                  We analyzed results from trials and series.Data Synthesis 
                  Idiopathic pulmonary fibrosis is an incurable disease with a dismal prognosis. The only treatment of proven benefit is LTx. Since the introduction of the Lung Allocation Score, IPF has become the most common indication for LTx in the United States. These patients have a limited life expectancy and benefit from early referral for transplant. Although controversial, the most recent data suggest that bilateral LTx is superior to single LTx in the population of patients with IPF. For this population, LTx increases the length and quality of their lives.Conclusion 
                  Although patients with IPF have a dismal prognosis, LTx is a safe and effective treatment to improve their survival and functional status.